← Exelixis overview

Exelixis vs Chugai Pharmaceutical Co.: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Exelixis Inc (EXEL)

Q3 2026
▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

  • Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.

    This is the main new pipeline catalyst that could add a second major revenue stream.

  • Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.

    This is the key negative that explains why guidance was cut and tempers the growth story.

  • Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.

    This shows financial strength and a concrete action that can lift the stock price.

  • Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.

    This provides a counterweight to the guidance cut and shows the base business is healthy.

August 2026
▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

  • Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.

    This is the main new pipeline catalyst that could add a second major revenue stream.

  • Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.

    This is the key negative that explains why guidance was cut and tempers the growth story.

  • Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.

    This shows financial strength and a concrete action that can lift the stock price.

  • Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.

    This provides a counterweight to the guidance cut and shows the base business is healthy.

Latest
▲3▼1

Exelixis: Zanza Nears Launch, Cabometyx NET Ramp Lags

  • Zanzalintinib launch preparation Exelixis is preparing to launch zanzalintinib in third-line colorectal cancer after the FDA accepted its application with a December 3, 2026 decision date. The company sees a $1.5 billion market opportunity, giving EXEL a new growth driver beyond its flagship Cabometyx.

    This is the main new pipeline catalyst that could add a second major revenue stream.

  • Cabometyx NET ramp slower than expected Exelixis lowered its 2026 revenue guidance by $50 million because the neuroendocrine tumor launch of Cabometyx is ramping more slowly than planned. The company says the gap is temporary, but it means near-term sales will be lower than hoped.

    This is the key negative that explains why guidance was cut and tempers the growth story.

  • Strong Q2 results and new buyback Exelixis beat second-quarter earnings estimates and announced a new $750 million share repurchase program after completing the previous one. The buyback can support the stock price by reducing the number of shares outstanding.

    This shows financial strength and a concrete action that can lift the stock price.

  • Cabometyx franchise remains solid Cabometyx sales grew about 10% year-over-year, and Exelixis still aims for a $3 billion franchise. It holds roughly 47% of new-patient share in neuroendocrine tumors, showing the core business is still expanding even if the launch is slower than expected.

    This provides a counterweight to the guidance cut and shows the base business is healthy.

Chugai Pharmaceutical Co., Ltd. (4519.JP)

Q3 2026
▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

  • First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.

    It shows the company's underlying earnings strength, a key reason investors hold the stock.

  • Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.

    It explains why the stock dropped even though profits rose, a key driver of sentiment.

  • Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.

    It is the main negative event of the period, directly hitting the stock price.

  • Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.

    It shows a potential recovery path after the negative news, balancing the picture.

August 2026
▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

  • First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.

    It shows the company's underlying earnings strength, a key reason investors hold the stock.

  • Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.

    It explains why the stock dropped even though profits rose, a key driver of sentiment.

  • Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.

    It is the main negative event of the period, directly hitting the stock price.

  • Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.

    It shows a potential recovery path after the negative news, balancing the picture.

Latest
▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

  • First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.

    It shows the company's underlying earnings strength, a key reason investors hold the stock.

  • Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.

    It explains why the stock dropped even though profits rose, a key driver of sentiment.

  • Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.

    It is the main negative event of the period, directly hitting the stock price.

  • Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.

    It shows a potential recovery path after the negative news, balancing the picture.